Evaluating the Current Landscape of Acute Lymphocytic Leukemia

Nitin Jain, MD, explains the key takeaways from multiple discussions on acute lymphoblastic leukemia which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.

Nitin Jain, MD, associate professor in the department of leukemia, division of cancer medicine, at the University of Texas MD Anderson Cancer Center, explains the key takeaways from multiple discussions on acute lymphoblastic leukemia (ALL) which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.

During a session on the first day of the meeting, experts, including Jain, discussed different aspects of ALL, including pediatric data, minimal residual disease (MRD), and allogeneic chimeric antigen receptor (CAR) T cells within the space.

In the talk, Jain noted the evolving importance of allogeneic CAR T cells in ALL and how the future of this space aims to examine its efficacy compared with autologous CAR T.


Transcription:

0:08 | I think in the session this morning, we had 3 fantastic talks. One talked about the pediatric data and the younger data in ALL, another talk was on the MRD in ALL, and the third talk which I gave was in the allogeneic CAR T cells. Overall, I think it was good to see I think there are different aspects of things which are being developed. We learned the use that continues to be important for children and young adults. We learned that MRD techniques are being refined, and there are next generation sequencing technologies which are coming along more in the context of ALL.


0:45 | The talk which I gave about allogeneic CARs, is a space which is evolving, and we have to see how things pan out in the next 1 to 2 years. But I think if allogeneic CARs were to show equal efficacy to autologous CARs, that will be a game changer in terms of how we are approaching CAR T for these patients.